靶向P2Y13受体抑制IL-33和HMGB1释放并改善实验性哮喘
该研究探讨嘌呤能GPCR P2Y13-R对警报素IL-33和HMGB1释放的调控及其在哮喘中的作用。气源性过敏原或病毒通过ATP/ADP激活P2Y13-R,诱导气道上皮细胞核转位并释放IL-33和HMGB1;基因缺失或药物拮抗P2Y13可阻断该反应,减轻小鼠哮喘发作及鼻病毒相关急性加重,并增强抗病毒免疫。
要点
- P2Y13-R是IL-33和HMGB1释放的新型门控受体。
- 遗传缺失或药物拮抗P2Y13可减轻实验性哮喘发作与加重。
- P2Y13-R拮抗可增强IFN-λ产生并降低肺部病毒载量。
核心结论
- P2Y13-R是核警报素IL-33和HMGB1的新型门控受体,靶向该GPCR可预防实验性哮喘的发作和加重。
研究设计与样本
- 研究纳入健康受试者和哮喘患者支气管活检标本,并使用原代人氣道上皮细胞、原代小鼠气道上皮细胞及C57Bl/6小鼠。
- 通过药理学拮抗剂和P2Y13-R基因缺失小鼠评估P2Y13-R在气道上皮细胞功能及实验性哮喘发作、进展和加重中的作用。
主要发现
- 气源性过敏原暴露诱导ADP和ATP的细胞外释放,这些核苷酸可激活P2Y13-R。
- ATP、ADP、过敏原(屋尘螨、蟑螂或链格孢抗原)或病毒暴露诱导IL-33和HMGB1的核转位及后续释放,该反应被P2Y13基因缺失或药理学拮抗所消除。
- 在小鼠中,预防性或治疗性P2Y13-R阻断减轻哮喘发作,并在高保真慢性哮喘实验模型中消除鼻病毒相关加重的严重程度。
- P2Y13-R拮抗解除抗病毒免疫抑制,增加IFN-λ产生并降低肺部病毒载量。
临床怎么用
- P2Y13-R可作为哮喘尤其是病毒诱发加重的潜在治疗靶点,但尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The alarmins IL-33 and HMGB1 (high mobility group box 1) contribute to type 2 inflammation and asthma pathogenesis. Objectives: To determine whether P2Y13-R (P2Y13 receptor), a purinergic GPCR (G protein-coupled receptor) and risk allele for asthma, regulates the release of IL-33 and HMGB1. Methods: Bronchial biopsy specimens were obtained from healthy subjects and subjects with asthma. Primary human airway epithelial cells (AECs), primary mouse AECs, or C57Bl/6 mice were inoculated with various aeroallergens or respiratory viruses, and the nuclear-to-cytoplasmic translocation and release of alarmins was measured by using immunohistochemistry and an ELISA. The role of P2Y13-R in AEC function and in the onset, progression, and exacerbation of experimental asthma was assessed by using pharmacological antagonists and mice with P2Y13-R gene deletion. Measurements and Main Results: Aeroallergen exposure induced the extracellular release of ADP and ATP, nucleotides that activate P2Y13-R. ATP, ADP, and aeroallergen (house dust mite, cockroach, or Alternaria antigen) or virus exposure induced the nuclear-to-cytoplasmic translocation and subsequent release of IL-33 and HMGB1, and this response was ablated by genetic deletion or pharmacological antagonism of P2Y13. In mice, prophylactic or therapeutic P2Y13-R blockade attenuated asthma onset and, critically, ablated the severity of a rhinovirus-associated exacerbation in a high-fidelity experimental model of chronic asthma. Moreover, P2Y13-R antagonism derepressed antiviral immunity, increasing IFN-λ production and decreasing viral copies in the lung. Conclusions: We identify P2Y13-R as a novel gatekeeper of the nuclear alarmins IL-33 and HMGB1 and demonstrate that the targeting of this GPCR via genetic deletion or treatment with a small-molecule antagonist protects against the onset and exacerbations of experimental asthma.
引用
- Werder, Ullah, Rahman, et al. Targeting the P2Y13 Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental Asthma. Am J Respir Crit Care Med. 2022. PMID: 34860143. doi:10.1164/rccm.202009-3686OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。